本文選題：非小細(xì)胞肺癌（NSCLC） + 多藥耐藥蛋白��； 參考：《大連醫(yī)科大學(xué)》2012年碩士論文

【摘要】：目的：為了研究多藥耐藥基因MRP1在非小細(xì)胞肺癌中表達(dá)的差異，以及觀察siRNA干擾技術(shù)是否能有效抑制非小細(xì)胞肺癌耐藥細(xì)胞株中M RP1的表達(dá)，探討體外高效和特異逆轉(zhuǎn)肺癌耐藥的策略。 方法：運(yùn)用實(shí)時(shí)熒光定量PCR、免疫組化法檢測(cè)30例NSCLC組織及癌旁組織標(biāo)本中耐藥基因MRP1mRNA及其蛋白的表達(dá)水平，并且以MRP1為靶標(biāo)設(shè)計(jì)合成siRNA，直接轉(zhuǎn)染入A549/DDP，轉(zhuǎn)染前后用實(shí)時(shí)熒光定量PCR檢測(cè)MRP1mRNA表達(dá)水平，用Western blot檢測(cè)MRP1蛋白的表達(dá)，MTT法檢測(cè)A549/DDP對(duì)順鉑耐藥性的變化。 結(jié)果：1.在30例病理組織中，MRP1蛋白在肺癌組織中的陽性率為70%（21/30），癌旁組織中的陽性率為16.67%（5/30），表達(dá)有統(tǒng)計(jì)學(xué)差異(P0.05)；對(duì)于癌組織，MRP1蛋白在已經(jīng)化療的病理組織中陽性率為90.9%(10/11)，在未化療的病理組織中陽性率為57.89%(11/19)，，計(jì)算兩者有統(tǒng)計(jì)學(xué)差異(P0.05)，說明MRP1在已化療的組織中高表達(dá)。而且PCR結(jié)果顯示MRP1mRNA在癌組織中的表達(dá)也高于癌旁組織，經(jīng)過統(tǒng)計(jì)學(xué)分析有明顯差異(P0.01)。 2.體外實(shí)驗(yàn)中A549/DDP轉(zhuǎn)染MRP1siRNA后,MRP1mRNA表達(dá)明顯降低，和轉(zhuǎn)染前相比較有顯著性差異(P0.05)，抑制率達(dá)到了78%。轉(zhuǎn)染后MRP1蛋白相對(duì)表達(dá)強(qiáng)度從之前的0.820±0.037降低為0.435±0.042有明顯差異(P0.05)；MTT結(jié)果顯示轉(zhuǎn)染后A549/DDP對(duì)順鉑的敏感性增加了1.43倍。 結(jié)論：1.多藥耐藥基因MRP1在肺癌組織中的高表達(dá),且MRP1蛋白在化療的非小細(xì)胞肺癌組織中表達(dá)高于未化療組織，說明在非小細(xì)胞肺癌患者中存在原發(fā)性耐藥。 2.體外實(shí)驗(yàn)證實(shí)了在耐藥細(xì)胞轉(zhuǎn)染MRP1siRNA后MRP1的轉(zhuǎn)錄和翻譯都受到了不同程度的抑制，也使其對(duì)順鉑的藥物敏感性增強(qiáng)，從一定程度上說明了逆轉(zhuǎn)耐藥。
[Abstract]:Objective: to study the difference of multidrug resistance gene MRP1 expression in non-small cell lung cancer (NSCLC) and whether siRNA interference can effectively inhibit the expression of M RP1 in NSCLC cell lines. Objective: to study the strategy of reversing drug resistance of lung cancer in vitro. Methods: the expression of drug resistance gene MRP1mRNA and its protein in 30 cases of NSCLC and its adjacent tissues were detected by real-time fluorescence quantitative PCR and immunohistochemistry. SiRNAs were designed and synthesized with MRP1 as target and transfected directly into A549 / DDP. The expression of MRP1mRNA was detected by real-time quantitative PCR before and after transfection, and the expression of MRP1 protein was detected by Western blot. The change of cisplatin resistance of A549/DDP to cisplatin was detected by Western blot assay. The result is 1: 1. The positive rate of MRP1 protein was 70% in lung cancer tissue and 16.67% 5 / 30% in paracancerous tissue, and the positive rate of MRP1 protein was 90.9% / 1111% in cancer tissues which had already been treated with chemotherapy, and the positive rate of MRP1 protein was 16.67% 5 / 30% in adjacent tissues, and the positive rate of MRP1 protein in cancer tissues was 90.9% / 1111% in chemotherapeutic pathological tissues, and the positive rate of MRP1 protein was 16.67% 5 / 30% in adjacent tissues of lung cancer. The positive rate of MRP1 was 57.89% and 11 / 19% in pathological tissues. There was a statistical difference between the two groups (P 0.05), which indicated that MRP1 was highly expressed in the tissues that had been treated with chemotherapy. PCR results showed that the expression of MRP1mRNA in cancer tissues was higher than that in paracancerous tissues, and the difference was statistically significant (P 0.01). 2. The expression of MRP1 mRNA in MRP1siRNA transfected with A549/DDP was significantly lower than that before transfection, and the inhibitory rate was 78%. The relative expression intensity of MRP1 protein decreased from 0.820 鹵0.037 to 0.435 鹵0.042 after transfection. The results showed that the sensitivity of A549/DDP to cisplatin increased by 1.43 times after transfection. Conclusion 1. The high expression of multidrug resistance gene MRP1 in lung cancer tissues and the expression of MRP1 protein in non-small cell lung cancer tissues were higher than those in non-small cell lung cancer tissues, indicating that there was primary drug resistance in patients with non-small cell lung cancer. 2. In vitro experiments confirmed that the transcription and translation of MRP1 were inhibited in different degrees after transfection of drug resistant cells into MRP1siRNA, which also enhanced the drug sensitivity to cisplatin, which indicated that the drug resistance was reversed to some extent.
【學(xué)位授予單位】：大連醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2012
【分類號(hào)】：R734.2;R3416

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 任淑華,張偉,曲平,劉義,王井偉,張林;RNA干擾C-erbB-2對(duì)肺腺癌細(xì)胞calu-3增殖的影響[J];癌癥;2005年10期

2 郝軍,王妍,李慶昌,王恩華,邱雪杉,劉云鵬;MRP在非小細(xì)胞肺癌和正常肺組織中表達(dá)及其預(yù)后意義的研究[J];中國(guó)肺癌雜志;2005年01期

3 高峗;蘇丹;應(yīng)莉莎;呂汪霞;馬勝林;;RNA干擾ERCC1基因表達(dá)對(duì)肺腺癌細(xì)胞A549/DDP順鉑耐藥的影響[J];中國(guó)肺癌雜志;2010年09期

4 張梅春;胡成平;;肺癌順鉑耐藥的分子機(jī)制[J];國(guó)際呼吸雜志;2006年02期

5 張萍,王大章,鄭光勇,劉曙光;熱療對(duì)腫瘤細(xì)胞耐藥性的影響[J];華西口腔醫(yī)學(xué)雜志;2003年02期

6 張艷霞;肖祖克;;RNA干擾逆轉(zhuǎn)肺癌的多藥耐藥性研究進(jìn)展[J];江西醫(yī)藥;2008年09期

7 徐萌;朱新海;盛良翮;;小分子干擾RNA對(duì)非小細(xì)胞肺癌MRP基因和藥物敏感性的影響[J];臨床腫瘤學(xué)雜志;2008年02期

8 錢曉萍,劉寶瑞;腫瘤多藥耐藥機(jī)制的研究進(jìn)展[J];腫瘤防治雜志;2004年04期

9 姜明來;張開基;李輝;李青云;鄒志;李萬成;;丙戊酸對(duì)肺癌細(xì)胞系A(chǔ)549增殖和凋亡影響的研究[J];中華腫瘤防治雜志;2008年12期

10 徐萌;;肺癌化療耐藥分子標(biāo)志及其逆轉(zhuǎn)研究[J];中國(guó)醫(yī)院用藥評(píng)價(jià)與分析;2007年06期

本文編號(hào)：1877755